Sugi Predict

Sugi Predict / Compounds / SCHEMBL897888

SCHEMBL897888

SCHEMBL897888

CCc1cc2c(cc1OC)C(C)(C)C(=O)CC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 2/20 0.39
▸ KMT2A Q03164 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ POLA1 P09884 2/20 0.38
▸ HSD17B1 P14061 1/20 0.37
▸ ALK Q9UM73 2/20 0.37
▸ HTR2A P28223 2/20 0.33
▸ CDK4 P11802 1/20 0.33
▸ CCND1 P24385 1/20 0.33
▸ GSK3B P49841 1/20 0.33
▸ HTR2C P28335 1/20 0.32
▸ HTR2B P41595 1/20 0.32
▸ PARP1 P09874 1/20 0.32
▸ STING1 Q86WV6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20004206 0.81 ALK (0.38) KMT2AALDH1A1MEN1HSD17B10ALK
SCHEMBL897525 0.80 ALK (0.43) ALDH1A1MAPTTSHRALKHTR2A
SCHEMBL20061137 0.80 S100B (0.38) KMT2AALDH1A1MAPTTSHRHSD17B10
SCHEMBL897012 0.80 HTR2A (0.45) KDM4ETSHRALKHTR2AHTR2C
SCHEMBL27087599 0.79 DRD2 (0.35) ALK
SCHEMBL27087529 0.78 HSD17B1 (0.40) ALDH1A1KDM4EMAPTHPGDTSHR
SCHEMBL20634800 0.78 — —
SCHEMBL20061173 0.77 S100B (0.38) KMT2AALDH1A1MAPTTSHRHSD17B10
SCHEMBL7812922 0.77 ALK (0.43) KMT2AALDH1A1MAPTHPGDPOLA1
SCHEMBL29940534 0.77 ALK (0.38) KMT2AALDH1A1KDM4EMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4321514-B1 COMPOUND HAVING ALK INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF CGENETECH SUZHOU CHINA CO LTD (CN) 2025-12-03 — — EP disclosed
US-20240246927-A1 COMPOUNDS WITH ALK INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF CGENETECH (SUZHOU, CHINA) CO., LTD. (CN) 2024-07-25 — — US disclosed
EP-4321514-A1 COMPOUND HAVING ALK INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF CGeneTech (Suzhou, China) Co., Ltd. (CN) 2024-02-14 — — EP disclosed
CN-115340523-B Compound with ALK inhibitory activity and preparation method and application thereof 盛世泰科生物医药技术(苏州)股份有限公司 2023-12-15 — — CN disclosed
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 — — US disclosed
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 — — US disclosed
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 — — US disclosed
WO-2022237813-A1 COMPOUND HAVING ALK INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF 盛世泰科生物医药技术(苏州)有限公司 2022-11-17 — — WO disclosed
CN-115340523-A Compound with ALK inhibitory activity and preparation method and application thereof 盛世泰科生物医药技术(苏州)有限公司 2022-11-15 — — CN disclosed
US-20220306578-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-29 — — US disclosed
US-9126931-B2 Tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-09-08 — — US disclosed
US-20150150845-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-06-04 — — US disclosed
US-20150150845-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-06-04 — — US disclosed
US-20150150845-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-06-04 — — US disclosed
EP-2441753-A1 TETRACYCLIC COMPOUND Chugai Seiyaku Kabushiki Kaisha (JP) 2012-04-18 — — EP disclosed
EP-2441753-A1 TETRACYCLIC COMPOUND Chugai Seiyaku Kabushiki Kaisha (JP) 2012-04-18 — — EP disclosed
US-20120083488-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA 2012-04-05 — — US disclosed
US-20120083488-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA 2012-04-05 — — US disclosed
US-20120083488-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA 2012-04-05 — — US disclosed
WO-2010143664-A1 TETRACYCLIC COMPOUND 中外製薬株式会社 (JP) 2010-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142119-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 TAAR1 522/4885KMT2A 609/4885ALDH1A1 1165/4885
US-20120083488-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 TAAR1 522/4885KMT2A 609/4885ALDH1A1 1165/4885
US-20240246927-A1 COMPOUNDS WITH ALK INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF ALK, ACVR1, ALKBH3 TAAR1 3273/4885KMT2A 1307/4885ALDH1A1 571/4885
US-20220306578-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 TAAR1 522/4885KMT2A 609/4885ALDH1A1 1165/4885
US-20150150845-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 TAAR1 522/4885KMT2A 609/4885ALDH1A1 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.